Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

Phase 2 study of lusutrombopag (S-888711) in adults with immune thrombocytopenia (ITP) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• lusutrombopag (lusutrombopag)

Snippet

Sponsor: Shionogi | Conditions: Immune Thrombocytopenia (ITP) | Phase 2 | Status: TERMINATED | Results posted: 2021-02-24